Yoshihiro Noda1,2, Mera S Barr1,2,3, Reza Zomorrodi1,2, Robin F H Cash4,5,6, Tarek K Rajji1,7, Faranak Farzan1,2,7, Robert Chen4,5, Tony P George2,3, Zafiris J Daskalakis1,2,7, Daniel M Blumberger1,7. 1. Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, ON, Canada. 2. Department of Psychiatry, University of Toronto, Toronto, ON, Canada. 3. Addictions Division, Centre for Addiction and Mental Health, Toronto, ON, Canada. 4. Division of Neurology, Department of Medicine, University of Toronto, Toronto, ON, Canada. 5. Division of Brain, Imaging and Behaviour-Systems Neuroscience, Krembil Research Institute, University Health Network, Toronto, ON, Canada. 6. Monash Alfred Psychiatry Research Centre, Monash University Central Clinical School and The Alfred, Melbourne, Australia. 7. Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Abstract
BACKGROUND: Cholinergic dysfunction is increasingly assumed to be involved in the pathophysiology of schizophrenia. Short-latency afferent inhibition (SAI) is a transcranial magnetic stimulation (TMS) paradigm that has been shown to assay central cholinergic activity from the motor cortex (M1). Recently, we established a method to index SAI from the dorsolateral prefrontal cortex (DLPFC), an area implicated in the pathophysiology of schizophrenia. We investigated SAI in M1 and DLPFC in schizophrenia. We hypothesized that modulation of N100 on TMS-evoked potentials (TEPs) from the DLPFC would be attenuated in patients with schizophrenia compared to healthy controls. METHODS: SAI was examined in 12 patients, whose age was matched to controls, using TMS combined with electroencephalography (EEG). SAI was recorded with TMS applied to left M1 (M1-SAI) and DLPFC (DLPFC-SAI). For group comparison, we used the SAI data of healthy participants in our previous study. RESULTS: In patients, N100 TEP was significantly attenuated with DLPFC-SAI, whereas P180 TEP was significantly increased with M1-SAI. Between patients and controls, there were significant differences in modulation of P180 TEP by M1-SAI (t22 = -2.748, P = .012; patients > controls) and N100 TEP by DLPFC-SAI (t22 = 5.456, P < .0001; patients < controls). Further, modulation of N100 TEP by DLPFC-SAI significantly correlated with executive function (r = -.740, P = .006, N = 12). CONCLUSION: Our findings suggest that DLPFC-SAI but not M1-SAI were reduced in patients with schizophrenia and this was linked to deficits in cognition. This may reflect prefrontal cholinergic deficits and represent a biomarker for cholinergic and executive dysfunction in patients with schizophrenia.
BACKGROUND: Cholinergic dysfunction is increasingly assumed to be involved in the pathophysiology of schizophrenia. Short-latency afferent inhibition (SAI) is a transcranial magnetic stimulation (TMS) paradigm that has been shown to assay central cholinergic activity from the motor cortex (M1). Recently, we established a method to index SAI from the dorsolateral prefrontal cortex (DLPFC), an area implicated in the pathophysiology of schizophrenia. We investigated SAI in M1 and DLPFC in schizophrenia. We hypothesized that modulation of N100 on TMS-evoked potentials (TEPs) from the DLPFC would be attenuated in patients with schizophrenia compared to healthy controls. METHODS: SAI was examined in 12 patients, whose age was matched to controls, using TMS combined with electroencephalography (EEG). SAI was recorded with TMS applied to left M1 (M1-SAI) and DLPFC (DLPFC-SAI). For group comparison, we used the SAI data of healthy participants in our previous study. RESULTS: In patients, N100 TEP was significantly attenuated with DLPFC-SAI, whereas P180 TEP was significantly increased with M1-SAI. Between patients and controls, there were significant differences in modulation of P180 TEP by M1-SAI (t22 = -2.748, P = .012; patients > controls) and N100 TEP by DLPFC-SAI (t22 = 5.456, P < .0001; patients < controls). Further, modulation of N100 TEP by DLPFC-SAI significantly correlated with executive function (r = -.740, P = .006, N = 12). CONCLUSION: Our findings suggest that DLPFC-SAI but not M1-SAI were reduced in patients with schizophrenia and this was linked to deficits in cognition. This may reflect prefrontal cholinergic deficits and represent a biomarker for cholinergic and executive dysfunction in patients with schizophrenia.
Authors: S Leonard; C Breese; C Adams; K Benhammou; J Gault; K Stevens; M Lee; L Adler; A Olincy; R Ross; R Freedman Journal: Eur J Pharmacol Date: 2000-03-30 Impact factor: 4.432
Authors: Kristi A Sacco; Angelo Termine; Aisha Seyal; Melissa M Dudas; Jennifer C Vessicchio; Suchitra Krishnan-Sarin; Peter I Jatlow; Bruce E Wexler; Tony P George Journal: Arch Gen Psychiatry Date: 2005-06
Authors: Sung Wook Chung; Nigel C Rogasch; Kate E Hoy; Caley M Sullivan; Robin F H Cash; Paul B Fitzgerald Journal: Hum Brain Mapp Date: 2017-11-09 Impact factor: 5.038
Authors: Sung Wook Chung; Caley M Sullivan; Nigel C Rogasch; Kate E Hoy; Neil W Bailey; Robin F H Cash; Paul B Fitzgerald Journal: Hum Brain Mapp Date: 2018-09-25 Impact factor: 5.038
Authors: Tomasz A Jarczok; Friederike Roebruck; Lena Pokorny; Lea Biermann; Veit Roessner; Christoph Klein; Stephan Bender Journal: Front Neurosci Date: 2021-03-12 Impact factor: 4.677
Authors: T Hebel; B Langguth; M Schecklmann; S Schoisswohl; S Staudinger; A Schiller; L Ustohal; T Sverak; M Horky; T Kasparek; T Skront; M Hyza; T B Poeppl; M L Riester; L Schwemmer; S Zimmermann; K Sakreida Journal: Contemp Clin Trials Commun Date: 2022-01-20